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Effect of Pulsed Dexamethasone 
Therapy on Tolerance of Intravenously 
Administered Lipids in Extremely Low 
Birth Weight Infants 
J Sentipal-Walerius, S Dolberg, F hlimouni, et a1 
Department of Pediatrics, hlagee-Women’s Hospital, 
Pitts b 11 rgli, and Depart in en t of Neon a tology, L is 
Maternity Hospital, Tel Auiu Medical Center, Israel 
ABSTRACT We investigated the effect of dexamethasone on 
parenteral lipid tolerance in 7-day-old extremely low birth weight 
infants (n = 28) in a randomized, double-blind trial. Serum 
triglycerides were measured before and after 3 days of dexameth- 
asone or placebo treatment. Infants treated with dexamethasone 
responded with higher triglyceride concentrations and greater 
sensitivity to incremental increases in the intravenous lipid dose. 
(J Pediatr134:229-232, 1999) 
COMMENT Intravenous lipid emulsions may be associ- 
ated with increased serum triglyceride concentrations 
(STC). Increases in STC depend on the lipid dose, concen- 
tration, and the presence of hypertriglyceridemia-pre- 
disposing factors. Extremely-low-birth-weight infants 
(ELBWI <lo00 g birth weight) have reduced lipid clear- 
ance because of reduced lipoprotein lipase activity and 
limited adipose tissue mass. Corticosteroids possibly 
increase STC by increasing the synthesis of triglyceride- 
rich lipoproteins, reducing lipoprotein lipase activity, or 
altering insulin secretion. 
This placebo-controlled study assessed the effect of 
therapeutic intravenous dexamethasone therapy on the 
tolerance of 20% intravenous lipids in ELBWI. The two 
study groups did not differ significantly at  baseline. STC 
were measured before and after therapy. The treatment 
group received dexamethasone (0.5 mg/kg/d) for 3 consec- 
utive days. Lipids were continuously infused throughout 
therapy. Dextrose infusion rates and lipid doses were 
within normal dosage ranges. Study results showed sig- 
nificantly higher after-treatment STC in the dexametha- 
sone-treated infants compared with the placebo group. A 
dose-response relationship was observed between the 
lipid dose and STC in the dexamethasone group but not 
with placebo. Study limitations were discussed. 
Study findings indicate that dexamethasone may 
increase STC in ELBWI receiving intravenous lipid emul- 
sions. hlonitoring STC is warranted, and reducing the 
lipid dose may be necessary. 
Imad F. Btaiche, PharmD, BCNSP 
Randomized Trial of “Slow” Versus 
“Fast” Feed Advancements on the 
Incidence of Necrotizing Enterocolitis in 
Very Low Birth Weight Infants 
SF Rayyis, N Ambalavanan, L Wright, WA Carlo 
Department of Pediatrics, Uniuersity of Alabama at 
Birni ingham 
ABSTRACT Objeclice: To determine whether the rate of feed 
advancement affects the incidence of necrotizing enterocolitis 
(NEC). Study Design: Prospective randomized controlled trial 
involving 165 formula-fed infants with birth weight 501 to 1500 g 
and gestational age </=34 weeks. Infants were randomized into 
2 groups: “slow” (n = 98), who received 15 c&g/d increments (a 
10-day schedule to full feeds) and “fast” (n = 871, who received 35 
cc/kg/d increments (a 5-day schedule to full feeds) of Similac 
Special Care 20 caVoz. Feeds were increased only if well tolerated 
as defined by a protocol. Results: The incidence of NEC (Bell stage 
>/=II) was similar in both groups (slow 139 and fast 9 4 ,  P =.5). 
The incidence of perforation (Bell stage 111) was also similar in 
both groups (slow 4 4  and fast 2%, P =.8). Feeds were started a t  
a comparable postnatal age in both groups (median age: slow 5 
days and fast 4 days, P =.9). Although the neonates in the fast 
group attained full enteral intake earlier (median days 125th and 
75th percentiles]: slow 15 [12,21] and fast 11 [8, 151, P <.001) and 
regained their birth weight earlier (slow 15 [ l l ,  201 and fast 12 [6, 
151, P <.05), their ages a t  discharge mere not statistically 
different (slow 47 [31, 671 and fast 43 [29, 621, P =.3). Conclu- 
sions: A greater than twofold difference in the rate of feed 
advancement from 15 c&g/d to 35 cc/kg/d did not affect the 
incidence of NEC >/= stage 11. Factors other than feed advance- 
ment appear to be more important in the pathogenesis or pro- 
gression of NEC. (J Pediatr 134:293-297, 1999) 
COMMENT: NEC continues to be the bugaboo of enteral 
nutrition support in neonatal nurseries. This group was 
involved in a prior case-control study that showed a 16% 
incidence of NEC during a period in which a “fzst” feeding 
approach was often used a t  their clinical center. 
that “slow” feed advancement would decrease the inci- 
dence of NEC. However, only 56% of the infants in the fast 
group actually reached full feeds in the expected 5 days; in 
the slow group, 47% of the group actually reached full 
feeds in the expected 10 days. The range of time to full 
feeds was not described. A thorough feeding protocol that 
involved checking aspirates and conducting an abdominal 
examination was used prior to each feed. Feedings could 
be held or stopped, depending on the results. Obviously, 
feedings were held, because approximately half of both 
groups did not reach target feeds in the allotted time. So a 
more apt title for the study would be: “Intention to Use 
‘Fast’ Versus ‘Slow’ Feeding Advancements.” Perhaps a 
The authors hypothesis for this prospective study was. 
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difference in the incidence of NEC in this study group w a s  
due to the establishment of a feeding protocol with a very 
careful evaluation of the infant prior to each feed. 
Jacqueline Jones Wessel, hlEd, RD, CNSD, CSP 
Feeding Strategies for Premature 
Infants: Randomized Trial of 
Gastrointestinal Priming and 
Tube-Feeding Method 
RJ Schanler, RJ Shulman, C Lau, e t  a1 
US Department of AgriculturelAgricultural Research 
Service, Children’s Nutrition Research Center, Houston, 
Texas 
ABSTRACT Background: Data on enteral feeding manage- 
ment of premature infants are limited and often not the subject of 
randomized clinical trials. Several small studies suggest benefits 
from the early initiation of feeding, but do not assess the com- 
bined effects of time of initiation of feeding, tube-feeding method, 
and type of milk used. Either singly or  in combination, these 
treatments may affect growth, bone mineralization, biochemical 
measures of nutritional status, and feeding tolerance, and, ulti- 
mately, the duration of hospitalization. Methods: A total of 171 
premature infants, stratified by gestational age (26 to 30 weeks) 
and diet (human milk or preterm formula) were assigned ran- 
domly among four treatment combinations in a balanced two-way 
design comparing the presence or absence of gastrointestinal (GI) 
priming for 10 days and continuous infusion versus intermittent 
bolus tube-feeding. Results: The major outcome, time required for 
infants to attain full oral feeding, was similar among treatments. 
GI priming was not associated with any measured adverse effect 
and was associated with better calcium and phosphorus reten- 
tion, higher serum calcium and alkaline phosphatase activity, 
and shorter intestinal transit times. The bolus tube-feeding 
method was associated with significantly less feeding intolerance 
and greater rate of weight gain than the continuous method. In 
addition, the greater the quantity of human milk fed, the lower 
the morbidity. Conclusions: Early GI priming with human milk, 
using the bolus tube-feeding method, may provide the best 
advantage for the premature infant. (Pediatr 103:434-439,1999) 
COMMENT: As the authors pointed out in the introduc- 
tion to  this article, there are very few studies that have 
experimentally determined the best methods for providing 
enteral nutrition in premature infants. The conventional 
wisdom has been that continuous-drip feedings would be 
better tolerated. This derives from the approach in older 
children that are ill and may have alteration of their 
normal gastrointestinal motility. However, bolus feedings 
are actually more physiologic. This study demonstrated 
that the premature infant appears to tolerate bolus feed- 
ings with better tolerance than continuous-drip feeds. The 
philosophical question this raises is whether “healthy” 
premature infants are in a disease state or an altered 
stage (because of their extra-utero status) of normal devel- 
opment. 
The long-term benefits of gastrointestinal priming cer- 
tainly are also logical given that the gastrointestinal 
enterocyte receives its sustenance from the luminal con- 
tents. It is well recognized that a lack of enteral nutrition 
results in mucosal atrophy. That priming is beneficial in 
premature infants is not a new finding, but the number of 
infants included in this study further validates the safety 
of early low-level feedings. The benefits of human milk 
use, further confirmed by this study, are also well docu- 
mented. 
This study attempts a t  one stroke to establish the ideal 
method for feeding premature infants. Although this is 
one of the largest studies ever reported, the authors still 
ended up with smaller groups than was initially apparent, 
as infants were randomized into four groups because of 
the combinations of feeding options. The major outcome of 
time to attain full oral feedings was not significantly 
different between the groups, but the benefit of improved 
feeding tolerance and better weight gain mas apparent. 
The actual long-term benefits of better feeding tolerance 
may require larger patient numbers to document statisti- 
cal differences. Nonetheless, this study gives a scientific 
basis for an approach to nutrition in premature infants 
and may also indicate a necessity to change our philoso- 
phy of care in this subset of patients. 
hlark R. Corkins, hlD 
Total Parenteral Nutrition in the 
Critically 111 Patient: A Meta-Analysis 
DK Heyland, S MacDonald, L Keefe, e t  a1 
Department of Medicine, Queen’s University, Kingston, 
Ontario, Canada 
ABSTRACT Context: Nutritional support has become a stan- 
dard of care for hospitalized patients, but whether total paren- 
teral nutrition (TPN) affects morbidity and mortality is unclear. 
Objectioe: To examine the relationship between TPN and compli- 
cation and mortality rates in critically ill patients. Data Sources: 
Computerized search of published research on RIEDLINE from 
1980 to 1998, personal files, and review ofrelevant reference lists. 
Study Selection: We reviewed 210 titles, abstracts, and papers. 
Primary studies were included if they were randomized clinical 
trials of critically ill or surgical patients that evaluated the effect 
of TPN (compared with standard care) on complication and 
mortality rates. We excluded studies comparing TPN with enteral 
nutrition. Data Extraction: Relevant data mere abstracted on the 
methodology and outcomes of primary studies. Data were 
abstracted in duplicate, independently. Data Synthesis: There 
were 26 randomized trials of 2211 patients comparing the use of 
TPN with standard care (usual oral diet plus intravenous dex- 
trose) in surgical and critically ill patients. When the results of 
these trials were aggregated, TPN had no effect on mortality (risk 
ratio [RR], 1.03; 95% confidence interval [CI], 0.81-1.31). Patients 
who received TPN tended to have a lower complication rate, but 
this result was not statistically significant (RR, 0.84; 95% CI, 
0.64-1.09). We examined several a priori hypotheses and found 
that studies including only malnourished patients were associ- 
ated with lower complication rates but no difference in mortality 
when compared with studies of nonmalnourished patients. Stud- 
ies published since 1989 and studies with a higher methods score 
showed no treatment effect, while studies published in 1988 or 
before and studies with a lower methods score demonstrated a 
significant treatment effect. Complication rates were lower in 
studies that did not use lipids; however, there was no difference 
in mortality rates between studies that did not use lipids and 
those studies that did. Studies limited to critically ill patients 
demonstrated a significant increase in complication and mortal- 
ity rates compared with studies of surgical patients. Conclusions: 
Total parenteral nutrition does not influence the overall mortality 
rate of surgical or  critically ill patients. It may reduce the 
complication rate, especially in malnourished patients, but study 
results are influenced by patient population, use of lipids, meth- 
. 
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odological quality, and year of publication. (JAAIA 280:2013- 
2019, 1998) 
COMMENT RIeta-analysis is a process whereby studies 
that appear to be similar are combined to increase the 
power to define a true difference between the treatment 
and control groups. All 26 trials in this meta-analysis 
compared pa ren ted  nutrition (PN) with standard ther- 
apy (ie, no nutritional support INS]). Although the intent 
of Heyland and his colleagues was to assess the impact of 
PN in the critically ill, the vast majority of the trials 
involved one particular segment: surgical patients. 
It was disappointing that, even when data from 2211 
patients were combined, PN was not found to have any 
favorable effect on mortality or morbidity. This conclusion 
should not have been surprising, however; one needs only 
to review past meta-analyses to read similar perspectives. 
In fact, PN has been associated with higher rates of 
infectious morbidity in patients undergoing cancer chemo- 
therapy. 
When Heyland et  a1 only assessed the higher quality 
studies, the relative risks for both mortality and morbidity 
exceeded 1.0; that is, the PN may even have been of net 
harm. Hence, even if one believes that enteral nutrition is 
superior to PN in critically ill patients, one cannot thereby 
assume that this form of NS is better than no NS at  all. 
One lesson to be gleaned from this meta-analysis is that 
future trials of critically ill patients must include a true 
control group, namely, one not systematically provided 
with any NS. 
Ronald L. Koretz, RID 
